Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.72 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.72 |
| ▸ | MME | P08473 | 9/20 | 0.64 |
| ▸ | ACE | P12821 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497369 | 0.88 | CYP1A2 (0.68) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL4724923 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL29865739 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL4451600 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL2588080 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL40705 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL107422 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL28912638 | 0.86 | CYP1A2 (0.65) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL1559014 | 0.84 | FOLH1 (1.00) | CPA3FOLH1MMECYP1A2 | |
| SCHEMBL1464853 | 0.84 | FOLH1 (1.00) | CPA3FOLH1MMECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | NAT1, ZRANB2, TXN | CPA3 3093/4885FOLH1 3985/4885MME 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.